PFE Pfizer Inc.

The next test will come from much larger trials

Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.

Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.

A fat dividend yield can mean a generous payout or a stock the market has already written off, and right now six familiar names are flashing signals that suggest the difference matters more than ever.

A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, but four large-cap payers in real estate, telecom, tobacco, and healthcare are generating the cash flow to prove they still belong.

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.

Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.

While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.

Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.

Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Summit Therapeutics (SMMT) shares rose early Tuesday after British drugmaker AstraZeneca (AZN) agree

A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.

Pfizer (NYSE:PFE) is set to feature data from 45 oncology research abstracts at the upcoming ESMO Congress. The company plans multiple oral presentations on late-stage cancer candidates alongside results for established oncology medicines. New clinical readouts at ESMO will spotlight Pfizer's late-stage oncology pipeline and marketed cancer drugs, against a broader backdrop our research has surfaced. Take a look at 4 warning signs we have identified for Pfizer. For investors tracking how...

BioNTech (NASDAQ:BNTX) said on Monday that it will close manufacturing facilities in Germany and Singapore after a sales process for the sites did not result in completed transactions. The German vaccine maker had announced in May that it would seek buyers for facilities in Idar-Oberstein, Marburg and Tuebingen in Germany, as well as its Singapore site, with closures planned if purchasers could not be found.

AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly […]

Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COVID revenue declines and generic and biosimilar competition approaches. Medtronic, meanwhile, is […]

Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as […]

Pfizer Inc. (NYSE:PFE) has agreed to share a portion of the incremental net revenue it generates from higher drug prices overseas with the U.S. Department of Health and Human Services (HHS), according to newly released documents covering its Most Favored Nation (MFN) pricing agreement. The provision applies to medicines already on the market and runs […]

Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Both companies are years from commercial scale and burning cash to get there. The difference is in how long each can keep going.

On September 13, 2026, the Wall Street Journal reported that Pfizer Inc. (NYSE:PFE) is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees. Eurocontrol, the intergovernmental body that coordinates European air traffic management, has frozen transfers of airline route […]

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.

The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.

Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.

The 8:30 Hosts Julie Hyman, Pras Subramanian, and Jake Conley break down the biggest market and business stories driving the day's conversation. From the latest updates from President Trump's summit with Xi Jinping to Costco's (COST) latest earnings, The 8:30 panel delivers the essential headlines and market context you need to start your day informed. Deirdre Bosa also comes on to discuss her recent interview with Microsoft (MSFT) CEO Satya Nadella.

The 5-year U.S. Treasury yield stands at 5.04%. Arguably, U.S. sovereign debt is the safest investment in the world. A bit of doubt has crept in as U.S. debt topped $40 trillion. However, it remains a “sure thing” from an investment safety standpoint. As an alternative to the five-year U.S. paper, an investor could own […]

Pfizer (NYSE:PFE) is focusing more of its research pipeline on therapies eligible for FDA Breakthrough Therapy and orphan drug status. The FDA has widened use of Breakthrough Therapy designations in areas such as oncology, which can shorten review and approval timelines. Global orphan drug markets are expanding in value as genomics, faster approvals, and government incentives support treatments for rare diseases. The growing role of Breakthrough Therapy labels and orphan drugs for Pfizer is...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with […]

Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.

Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

As bond yields climb amid record U.S. debt, Vanguard's BSV and VCIT ETFs offer TTM yields of about 4% and 5%, respectively, with potential for rising monthly distributions.

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.

A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check. Six well-known names are flashing the exact warning signs that tend to show up just before a payout gets cut.